News & Events
2008 Press Releases
Eidogen-Sertanty Makes Validation Data Freely Available
San Diego, CA (May 29, 2008) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, today announced it has made freely available to the research community three sizable datasets from its popular Kinase Knowledgebase (KKB).
To help foster algorithmic development and validation efforts worldwide, Eidogen-Sertanty has launched a campaign to extract from its large knowledgebases a few sets of small, but useful data and then freely distribute to the general research community. The first in this campaign includes three structure-activity data sets from the Eidogen-Sertanty Kinase Knowledgebase.
Included in the first validation set release are a set of molecule structures and corresponding IC50 data across three Kinase targets: ABL1, SRC, and AURKA. This data can be downloaded from the following link:
"All too often scientists and engineers are stymied with having no or too little data to test, validate, publish or freely discuss, and thus establish credible utility for their methodologies," said Steve Muskal, CEO of Eidogen-Sertanty. "By distributing a few sets of carefully curated data to researchers, we are hoping to lower one of the many hurdles in technology development and validation."
For more information, please contact:
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.